TMCI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TMCI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Treace Medical Concepts's enterprise value is $313.1 Mil. Treace Medical Concepts's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was $-51.1 Mil. Therefore, Treace Medical Concepts's EV-to-EBITDA for today is -6.13.
The historical rank and industry rank for Treace Medical Concepts's EV-to-EBITDA or its related term are showing as below:
During the past 5 years, the highest EV-to-EBITDA of Treace Medical Concepts was 1097.78. The lowest was -1258.37. And the median was -32.67.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-09-22), Treace Medical Concepts's stock price is $5.44. Treace Medical Concepts's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-1.022. Therefore, Treace Medical Concepts's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Treace Medical Concepts's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Treace Medical Concepts Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
EV-to-EBITDA | - | - | -59.05 | -34.90 | -18.83 |
Treace Medical Concepts Quarterly Data | |||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -44.49 | -19.90 | -18.83 | -17.78 | -7.60 |
For the Medical Devices subindustry, Treace Medical Concepts's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Treace Medical Concepts's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Treace Medical Concepts's EV-to-EBITDA falls into.
Treace Medical Concepts's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 313.122 | / | -51.097 | |
= | -6.13 |
Treace Medical Concepts's current Enterprise Value is $313.1 Mil.
Treace Medical Concepts's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-51.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Treace Medical Concepts (NAS:TMCI) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Treace Medical Concepts's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 5.44 | / | -1.022 | |
= | At Loss |
Treace Medical Concepts's share price for today is $5.44.
Treace Medical Concepts's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.022.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Treace Medical Concepts's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
F Barry Bays | director | |
Betsy Hanna | director | C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE RD #150, PONTE VEDRA BEACH FL 32081 |
Deepti Jain | director | 3701 WAYZATA BLVD, MINNEAPOLIS MN 55416 |
Sean F. Scanlan | officer: See Remarks | C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081 |
James T Treace | director | 117 BRISTOL PLACE, PONTE VEDRA BEACH FL 32082 |
Richard W Mott | director | 1221 CROSSMAN AVENUE, SUNNYVALE CA 94089 |
Thomas E Timbie | director | |
Daniel E. Owens | officer: Chief HR Officer | C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081 |
Scot Michael Elder | officer: *See "Remarks" | C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081 |
Mark Hair | officer: Chief Financial Officer | C/O RESTORATION ROBOTICS, INC., 128 BAYTECH DRIVE, SAN JOSE CA 95134 |
Aaron Berutti | officer: Sr. VP, Sales | C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081 |
John T. Treace | director, 10 percent owner, officer: Chief Executive Officer | C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081 |
Lance A Berry | director | 5677 AIRLINE ROAD, ARLINGTON TN 38002 |
Jane E Kiernan | director | 525 W ROSCOE, CHICAGO IL 60657 |
John R Treace | director | 5677 AIRLINE RD, ARLINGTON VA 38002 |
From GuruFocus
By sperokesalga sperokesalga • 03-03-2023
By Marketwired • 08-22-2023
By Stock market mentor Stock market mentor • 02-07-2023
By sperokesalga sperokesalga • 06-01-2023
By Marketwired • 08-21-2023
By PRNewswire PRNewswire • 03-25-2023
By sperokesalga sperokesalga • 04-19-2023
By Marketwired • 07-12-2023
By Stock market mentor Stock market mentor • 02-08-2023
By Marketwired • 10-16-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.